Jubilant Organosys, headquartered at Noida, near New Delhi, has announced that its subsidiary Jubilant Biosys, based in Bangalore has developed a next-generation screening solution, Legend NGSS, that will further enable the process of high throughput screening, accelerating global drug discovery. The software to be launched in the US and Europe initially, allows scientists to capture, store, and analyse Oracle 9i/10g based screening data with flexibility, accuracy and speed.
Legend NGSS allows users to create rich visualisation and interactive analysis reports, including dose-response curves and scatter plot heat maps. The novel tool allows flexible and interactive mother to daughter plate mapping from any plate reader. This generates best-fit kinetic and time course assays, without internal IT intervention, complete management of compound and targeted libraries, and optimised on-the fly curve-fitting techniques.
"This novel screening tool for scientific, pharmaceutical and biotech communities around the world can enhance the productivity of pharmaceutical and biotech research," said Amit Rustagi, head-IT, Jubilant Biosys.
"This innovative product demonstrates Jubilant's strategy to develop and provide enabling technologies to accelerate the process of drug discovery and development," he added further.
Legend NGSS has been developed in collaboration with a global pharmaceutical company. It is available worldwide on a subscription basis, which includes comprehensive software support and training.
Your guide to the latest seat tally, live updates, analysis and list of winners for Lok Sabha Elections 2019 on firstpost.com/elections. Follow us on Twitter and Instagram or like our Instagram or like our Facebook page for updates from all 542 constituencies on counting day of the general elections.
Updated Date: Jan 31, 2017 02:06:57 IST